The document outlines the evolution and importance of Decentralized Clinical Trials (DCTs) within the PPD clinical research business of Thermo Fisher Scientific. It emphasizes the need for a flexible and adaptive ecosystem to meet the diverse requirements of clinical trials, particularly in a decentralized world. Key points include the importance of patient-centricity, the need for tailored trial designs, and the benefits of DCTs in improving patient diversity, reducing trial burdens, and enhancing data collection. The document also highlights the significance of leveraging digital tools, maintaining regulatory compliance, and ensuring effective data management to drive the success of DCTs.

Join for free to read